We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

9 hedge funds and large institutions have $275K invested in Scinai Immunotherapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

29% more funds holding

Funds holding: 7 → 9 (+2)

2.37% less ownership

Funds ownership: 13% → 10.63% (-2.4%)

48% less capital invested

Capital invested by funds: $534K → $275K (-$259K)

Holders
9
Holders Change
+2
Holders Change %
+28.57%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
+$1.24K
2
UBS Group
UBS Group
Switzerland
+$894
3
Credit Agricole
Credit Agricole
France
+$275
4
Morgan Stanley
Morgan Stanley
New York
+$206

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$90.4K
2
SM
Sabby Management
Florida
-$16.7K

SCNI Hedge Fund Activity: Q4 2023 in Review

9 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q4 2023, worth a combined $275K — down 48% from $534K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new SCNI positions and 0 closed out — a net gain of 2 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was RhumbLine Advisers, adding an estimated $1.24K. The largest seller was Armistice Capital, cutting an estimated $90.4K.

  • 9 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q4 2023, up from 7 in Q3 2023.
  • Funds reported $275K of Scinai Immunotherapeutics stock for Q4 2023, down 48% quarter-over-quarter.
  • 2 funds opened new Scinai Immunotherapeutics positions in Q4 2023 and 0 closed out, a net change of +2 holders.
  • The largest Scinai Immunotherapeutics buyer in Q4 2023 was RhumbLine Advisers, an estimated $1.24K added.
  • The largest Scinai Immunotherapeutics seller in Q4 2023 was Armistice Capital, an estimated $90.4K sold.

Based on aggregated 13F filings for Q4 2023.